secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0000719135-22-000030
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical Q1 revenue up 45% to $12.5M, net loss widens, guidance narrowed
----------------------------------------------------------------------------

- Revenue $12.5M (+45% YoY); Advanced Energy $10.8M (+41%), OEM $1.7M (+72%).
- Net loss attributable to stockholders $5.9M ($0.17/share) vs $4.9M ($0.14) prior year.
- Adjusted EBITDA loss $4.0M vs $3.4M; operating expenses rose 33% to $14.1M.
- FY2022 revenue guidance narrowed to $52.5-59.0M (prior $50-63M); Advanced Energy $46-52M (prior $43.5-56M).
- FDA Safety Communication in March impacted U.S. new customer adoption; 510(k) submissions for dermal/laxity pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000071913522000030/0000719135-22-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000071913522000030/apyx-20220512.htm
  HTML page:      https://secwatch.observer/filing/0000719135-22-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer